Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study  by Nicol, Mark P et al.
www.thelancet.com/infection   Vol 11   November 2011 819
Articles
Lancet Infect Dis 2011; 
11: 819–24
Published Online
July 18, 2011
DOI:10.1016/S1473-
3099(11)70167-0
See Comment page 802
Division of Medical 
Microbiology and Institute 
for Infectious Diseases and 
Molecular Medicine 
(Prof M P Nicol PhD, 
W Zemanay PhD), Division 
of Clinical Pharmacology, 
Department of Medicine 
(L Workman MSc), and 
Department of Paediatrics and 
Child Health (W Isaacs BSc, 
J Munro, F Black MBBCh, 
B Eley FCPaed, Prof H J Zar PhD), 
University of Cape Town, Cape 
Town, South Africa; National 
Health Laboratory Service, 
Groote Schuur Hospital, Cape 
Town, South Africa 
(Prof M P Nicol, W Zemanay); 
Red Cross War Memorial 
Children’s Hospital, Cape Town, 
South Africa (W Isaacs, J Munro, 
F Black, B Eley, Prof H J Zar); and 
Foundation for Innovative 
New Diagnostics (FIND), 
Geneva, Switzerland 
(C C Boehme MD)
Correspondence to:
Prof Mark P Nicol, 
5.28 Falmouth, Faculty of Health 
Sciences, Anzio Road, 
Observatory, Cape Town 7925, 
South Africa
mark.nicol@uct.ac.za
Accuracy of the Xpert MTB/RIF test for the diagnosis of 
pulmonary tuberculosis in children admitted to hospital in 
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Summary
Background WHO recommends that Xpert MTB/RIF replaces smear microscopy for initial diagnosis of suspected 
HIV-associated tuberculosis or multidrug-resistant pulmonary tuberculosis, but no data exist for its use in children. 
We aimed to assess the accuracy of the test for the diagnosis of pulmonary tuberculosis in children in an area with 
high tuberculosis and HIV prevalences. 
Methods In this prospective, descriptive study, we enrolled children aged 15 years or younger who had been admitted 
to one of two hospitals in Cape Town, South Africa, with suspected pulmonary tuberculosis between Feb 19, 2009, and 
Nov 30, 2010. We compared the diagnostic accuracy of MTB/RIF and concentrated, ﬂ uorescent acid-fast smear with a 
reference standard of liquid culture from two sequential induced sputum specimens (primary analysis). 
Results 452 children (median age 19·4 months, IQR 11·1–46·2) had at least one induced sputum specimen; 108 children 
(24%) had HIV infection. 27 children (6%) had a positive smear result, 70 (16%) had a positive culture result, and 58 
(13%) had a positive MTB/RIF test result. With mycobacterial culture as the reference standard, MTB/RIF tests when 
done on two induced sputum samples detected twice as many cases (75·9%, 95% CI 64·5–87·2) as did smear 
microscopy (37·9%, 25·1–50·8), detecting all of 22 smear-positive cases and 22 of 36 (61·1%, 44·4–77·8) smear-
negative cases. For smear-negative cases, the incremental increase in sensitivity from testing a second specimen was 
27·8% for MTB/RIF, compared with 13·8% for culture. The speciﬁ city of MTB/RIF was 98·8% (97·6–99·9). MTB/
RIF results were available in median 1 day (IQR 0–4) compared with median 12 days (9–17) for culture (p<0·0001). 
Interpretation MTB/RIF testing of two induced sputum specimens is warranted as the ﬁ rst-line diagnostic test for 
children with suspected pulmonary tuberculosis.
Funding National Institutes of Health, the National Health Laboratory Service Research Trust, the Medical Research 
Council of South Africa, and Wellcome Trust.
Introduction
Diagnosis of pulmonary tuberculosis in children has relied 
predominantly on clinical, radiological, and tuberculin 
skin-test ﬁ ndings.1 However, clinical diagnosis has low 
speciﬁ city, radiological interpretation is subject to 
interobserver variability, and the tuberculin skin test is a 
marker of exposure, not disease.1–3 Microbiological 
conﬁ rmation with identiﬁ cation of drug resistance is 
increasingly important in the context of an emerging drug-
resistant tuberculosis epidemic. Furthermore, conﬁ rmation 
is useful in children with HIV, in whom pill burden, drug 
interactions, and adherence issues make treatment of HIV 
and tuberculosis diﬃ  cult. Use of repeated induced sputum 
specimens in children is simple, well tolerated, and 
eﬀ ective for microbiological conﬁ rmation of pulmonary 
tuberculosis, even in infants.4,5 One induced sputum 
specimen provides a similar microbiological yield to three 
gastric lavage specimens in children admitted to hospital 
with pulmonary tuberculosis.4 
Smear microscopy is typically negative in children with 
culture-conﬁ rmed tuberculosis, even when optimised 
ﬂ uorescence microscopy is used on concentrated 
specimens. 1,6 Mycobacterial culture of induced sputum 
specimens is therefore needed, but culture can take weeks 
and is consequently unavailable to inform clinical 
decisions on initial treatment. A rapid diagnosis of 
tuberculosis in children is desirable because delayed 
diagnosis is associated with poor outcome.7 
An urgent need therefore exists for a rapid, sensitive, 
and speciﬁ c test for tuberculosis and for identiﬁ cation of 
drug-resistant disease in children. The performance of 
Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA), an 
integrated sample processing and nucleic acid ampliﬁ cation 
test for detection of Mycobacterium tuberculosis and 
resistance to rifampicin, was assessed in a large multicentre 
study in adults with suspected tuberculosis.8 One MTB/
RIF test accurately detected the presence of tuberculosis in 
98·2% of smear-positive and 72·5% of smear-negative 
tuberculosis cases. Rifampicin resistance was detected 
with a sensitivity of 99·1% and speciﬁ city of 100%. The test 
results were available within 100 min of testing, much less 
time than for results from culture.
WHO have endorsed the use of MTB/RIF as the initial 
diagnostic test in people suspected of having drug-
resistant or HIV-associated tuberculosis,9 but no data are 
available on its accuracy in children. We prospectively 
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assessed use of MTB/RIF compared with culture of 
repeated induced sputum specimens for the diagnosis of 
pulmonary tuberculosis in children.
Methods
Participants
We did a prospective study in the general paediatric 
wards of Red Cross War Memorial Children’s Hospital 
and Somerset Hospital, Cape Town, South Africa. 
Children aged 15 years or younger were eligible for 
enrolment if they had been admitted to hospital between 
Feb 19, 2009, and Nov 30, 2010, with pulmonary 
tuberculosis suspected on the basis of having a cough for 
more than 14 days and one of the following: a household 
contact infected with tuberculosis within the previous 
3 months, loss of weight or failure to gain weight in the 
previous 3 months, a positive skin test to puriﬁ ed protein 
derivative (PPD; 2TU, PPD RT23, Staten Serum Institute, 
Denmark, Copenhagen), or a chest radiograph suggestive 
of pulmonary tuberculosis. A positive skin test was 
deﬁ ned as 5 mm or more of transverse induration in 
children with HIV infection or 10 mm or more in children 
without HIV infection. Children were excluded if they 
had received more than 72 h of tuberculosis treatment or 
prophylaxis during their hospital admission, if they were 
not resident in Cape Town and could not be followed up, 
if informed consent was not obtainable, or if an induced 
sputum specimen could not be obtained. 
Consecutive children meeting the entry criteria were 
enrolled, except when patients were discharged before 
recruitment could be completed. Written, informed 
consent for enrolment in the study was obtained from a 
parent or legal guardian. The Research Ethics Committee 
of the University of Cape Town approved the study.
Procedures
A history and physical examination were done at 
enrolment. Routine clinical investigations included chest 
radiography, tuberculin skin test, and HIV testing in 
children whose HIV status was not known (HIV rapid test 
in all children, followed by a conﬁ rmatory PCR for children 
younger than 18 months or HIV ELISA for children aged 
18 months or older). Children with HIV infection were 
classiﬁ ed according to WHO clinical staging10 from stage 1 
to stage 4. We recorded CD4 cell count and HIV viral load 
for children with HIV; children were classiﬁ ed according 
to the US Centers for Disease Control and Prevention 
immunological classiﬁ cation11 as category 1 to category 3 
(no immune deﬁ ciency to severe immune deﬁ ciency). We 
did CD4 cell counts with the panleucogating method and 
viral load testing with Abbott RealTime HIV-1 assay 
(Abbott, Des Plaines, IL, USA). Two reviewers, masked to 
microbiological and other results, reported all chest 
radiographs according to a standardised format. 
Children were followed up for the duration of their stay 
in hospital. The decision to start tuberculosis treatment 
was at the discretion of the medical doctor caring for the 
child. Follow-up ambulatory visits were done at 3 months 
for all children to assign a diagnostic category by 
assessment of response to treatment or recovery in the 
absence of tuberculosis treatment. Response to treatment 
or recovery was assessed at follow-up visits by recording 
symptoms, signs, and weight gain, and by repeating 
chest radiograph at the completion of treatment. A study 
paediatrician who had access to all laboratory results 
made this assessment.
Sputum induction was done after a 2–3 h fast in a 
dedicated sputum induction room by a trained research 
nurse, as previously described.4 A second induced 
sputum specimen was obtained, whenever possible, the 
following day or a minimum of 4 h after the ﬁ rst 
specimen. Baseline arterial pulse oximetry was done in 
all children; monitoring was done throughout the sputum 
induction procedure and for 30 min thereafter.
Sputum specimens were processed within 2 h of 
collection in an accredited routine diagnostic microbiology 
laboratory by trained technicians who used standardised 
protocols. This laboratory also participated in the 
previously reported multicountry study of MTB/RIF.8 
After decontamination with N-acetyl-L-cysteine and 
sodium hydroxide (1·0% ﬁ nal concentration), centrifuged 
sputum deposits were resuspended in 1·5 mL of 
phosphate buﬀ er. A drop of sediment was used for 
ﬂ uorescent acid-fast smear microscopy. For MTB/RIF 
testing, 1·4 mL of MTB/RIF sample reagent was added to 
967 excluded
612 not eligible 
345 discharged 
10 withdrew consent
1459 children screened
492 children enrolled
40 excluded
33 without at least one valid 
induced sputum culture and 
MTB/RIF result 
7 with positive culture from 
another site
452 children with one induced 
sputum specimen
385 children with two induced 
sputum specimens
70 children with deﬁnite
tuberculosis 
52 MTB/RIF positive
27 smear positive 
216 with possible tuberculosis
6 MTB/RIF positive 
0 smear positive 
166 without tuberculosis
0 MTB/RIF positive 
0 smear positive 
Figure: Study proﬁ le
Articles
www.thelancet.com/infection   Vol 11   November 2011 821
0·7 mL of the resuspended sputum pellet and 
subsequently processed as previously reported.8 
Automated liquid culture (mycobacterial growth indicator, 
BACTEC MGIT, Becton Dickinson Microbiology 
Systems, Cockeysville, MD, USA) was done with 0·5mL 
of the resuspended pellet. Cultures were incubated for 
6 weeks if negative. Positive cultures were identiﬁ ed by 
acid-fast staining followed by MTBDRplus testing (Hain 
Lifesciences, Hehren, Germany)12 to conﬁ rm the presence 
of M tuberculosis and to test for resistance to rifampicin 
and isoniazid. When clinically indicated, hospital staﬀ  
collected specimens from additional disease sites—eg, in 
children with suspected extrapulmonary and pulmonary 
tuberculosis. Because culture results were not available 
at the time of MTB/RIF testing, staﬀ  doing and recording 
MTB/RIF tests were unaware of culture results.
If MTB/RIF or MTBDRplus tests identiﬁ ed the 
presence of rifampicin resistance, the corresponding 
cultured isolate also underwent testing for phenotypic 
resistance to rifampicin and isoniazid by automated 
liquid MGIT culture. 
On the basis of clinical and microbiological 
investigations children were classiﬁ ed as having deﬁ nite 
tuberculosis (induced sputum culture positive for 
M tuberculosis), not tuberculosis (negative tuberculosis 
cultures and documented resolution of symptoms and 
signs at 3 month follow-up visit in children who did not 
receive treatment), or possible tuberculosis (all other 
children). Children with possible tuberculosis therefore 
included children not receiving treatment, who had no 
documented recovery at follow-up, and all children placed 
on treatment in the absence of microbiological 
conﬁ rmation. An automatic computed algorithm made 
the assignment to diagnostic category. 
Statistical analysis
The primary reference standard was a positive culture for 
M tuberculosis from an induced sputum specimen. We 
analysed patients separately with interpretable results 
from at least one induced sputum specimen and those 
with results from two induced sputum specimens. For 
the primary analysis of the speciﬁ city of MTB/RIF we 
included only those children with two interpretable MTB/
RIF and culture results, because one negative culture 
result is likely to miss a substantial proportion of culture-
conﬁ rmed cases.4 We excluded children with negative 
induced sputum cultures who had a positive culture from 
another (extrapulmonary) site from the analysis of 
sensitivity and speciﬁ city, because of the diﬃ  culty in 
interpretation of MTB/RIF ﬁ ndings in this group. The 
sensitivity, speciﬁ city, and predictive values of the assays 
with 95% CIs were established. Data were analysed with 
Stata (version 10) and EpiInfo (version 6). Simple 
descriptive statistics were used to characterise the study 
population, normally distributed continuous data were 
summarised by mean and 95% CI, and non-normally 
distributed continuous data by median and IQR. 
Categorical data were summarised as proportions with 
95% CIs. Statistical tests included two-sample test of 
proportions, χ² test, and Wilcoxon rank-sum test. All 
statistical tests were two-sided at with an α value of 0·05.
Results
We screened 1459 children, 492 of whom were enrolled 
(ﬁ gure). 452 children had MTB/RIF and culture test 
results from at least one induced sputum specimen and 
385 had test results from two specimens. 70 (16%) of 
452 children were classiﬁ ed as having deﬁ nite tuberculosis, 
216 (48%) as having possible tuberculosis, and 166 (37%) 
as not having tuberculosis (table 1). Most children with 
HIV had moderate or severe immune suppression, and 
many children had nutritional impairment (table 1). 
At the time of enrolment, 34 children had previously 
been given tuberculosis treatment for a median 1 day—
no children received treatment for more than 3 days. 
Almost all children with deﬁ nite tuberculosis and most 
children with possible tuberculosis were given 
All 
(n=452)
Deﬁ nite 
(n=70)
Possible 
(n=216)
Not tuberculosis 
(n=166)
Median (IQR) age (months) 19·4 
(11·1 to 46·2)
23·7 
(15·2 to 59·5)
17·6 
(10·6 to 40·6) 
18·3 
(10·9 to 39·9)
Sex (male) 250 (55%) 39 (56%) 116 (54%) 95 (57%)
HIV infection 108 (24%) 17 (24%) 55 (26%) 36 (22%)
WHO clinical staging
Stage 1 15 (14%) 2 (13%) 7 (47%) 6 (40%)
Stage 2 43 (40%) 7 (16%) 20 (47%) 16 (37%)
Stage 3 27 (25%) 4 (15%) 13 (48%) 10 (37%)
Stage 4 23 (21%) 4 (17%) 15 (65%) 4 (17%)
HIV CDC immune suppression
None 11 (10%) 2 (18%) 7 (64%) 2 (18%)
Moderate 34 (31%) 3 (9%) 16 (47%) 15 (44%)
Severe 54 (50%) 9 (17%) 28 (52%) 17 (32%)
Unknown 9 (8%) 3 (33%) 4 (44%) 2 (22%)
History of tuberculosis 51 (11%) 7 (10%) 23 (11%) 21 (13%)
Radiological changes suggestive of 
tuberculosis 
274 (64%) 44 (68%) 139 (68%) 91 (57%)
Started on tuberculosis treatment 216 (48%) 69 (99%) 147 (68%) 0 
Median (IQR) height for age Z score  –1·50
(–2·5 to –0·5)
–1·58 
(–2·78 to –0·68)
–1·69 
(–2·7 to –0·71)
–1·28 
(–2·1 to –0·2)
Median (IQR) weight for 
age Z score
–1·5 
(–2·3 to –0·6)
–1·77 
(–2·86 to –0·89)
–1·52 
(–2·37 to –0·65)
–1·24 
(–2·16 to –0·43)
Median (IQR) weight for height 
Z score
–0·56 
(–1·6 to 0·4)
–0·93 
(–2·29 to –0·28)
–0·39 
(–1·53 to 0·53)
–0·39 
(–1·24 to 0·32)
Malnutrition (weight for age 
Z score <–2)
155 (34·3%) 31 (44·3%) 76 (35·2%) 48 (28·9%)
TST positive/TST result known (%)
All children 128/372 (34%) 39/57 (68%) 78/176 (44%) 11/139 (8%)
HIV-infected 13/85 (15%) 3/11 (27%) 10/44 (23%) 0/30
HIV-uninfected 115/287 (40%) 36/46 (78%) 68/132 (52%) 11/109 (10%)
Data are n (%) unless otherwise stated. CDC=US Centers for Disease Control and Prevention. TST=tuberculin skin test.
Table 1: Baseline characteristics 
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tuberculosis treatment on enrolment (table 1), and only 
one child—who had possible tuberculosis—did not 
improve on follow-up.
We recorded at least one positive MTB/RIF test in 
74·3% of children with deﬁ nite tuberculosis (table 2), 
2·8% of children with possible tuberculosis, and no 
children who did not have tuberculosis. MTB/RIF 
detected all 27 smear-positive deﬁ nite cases and 25 of 
43 smear-negative deﬁ nite cases (table 2). 
When including only the 385 children with both culture 
and MTB/RIF results from two induced sputum 
specimens, two MTB/RIF tests detected twice as many 
deﬁ nite cases as did smear microscopy, including all 
smear-positive cases but only 61·1% of smear-negative 
cases (table 2). The ﬁ rst MTB/RIF test detected all smear-
positive cases but only a third of smear-negative cases; 
the second test increased the sensitivity of MTB/RIF for 
smear negative tuberculosis by 27·8%. By comparison 
with MTB/RIF tests, a second test increased the sensitivity 
of culture by 13·8% (eight of 58 cases). 
The proportion of children diagnosed with deﬁ nite 
tuberculosis was much the same in HIV-infected 
(17 of 108, 15·7%) and uninfected children (53 of 344, 
15·4%). The sensitivity of MTB/RIF was higher in 
children with HIV than in children who did not have 
HIV (p=0·042; table 2). We recorded more smear-positive 
tuberculosis cases in children with HIV than in children 
without HIV, although the diﬀ erence was not signiﬁ cant 
(p=0·072; table 2). The speciﬁ city of MTB/RIF in children 
with two induced sputum culture results available was 
98·8%, with only four of 327 cases not detected (table 2). 
Two additional children had a positive MTB/RIF test with 
only one negative induced sputum culture result 
available. All of these six children were classiﬁ ed as 
having possible tuberculosis and had a documented 
response to treatment at 3 month follow-up, and probably 
had tuberculosis. None of the 166 children in the not 
tuberculosis group had a positive MTB/RIF result 
(speciﬁ city 100%, 95% CI 97·8–100). The speciﬁ city of 
smear microscopy in this group was also 100%.
When results for rifampicin susceptibility testing were 
interpretable from both line probe assay and MTB/RIF, 
MTB/RIF correctly identiﬁ ed all 70 rifampicin- susceptible-
cases and two rifampicin-resistant cases on a per-sample 
analysis (table 3). However, we recorded one case of 
rifampicin-resistant tuberculosis and four cases of 
rifampicin-sensitive tuberculosis (by line-probe assay and 
conﬁ rmatory culture-based testing), which were reported 
as indeterminate by MTB/RIF. Whenever rifampicin 
resistance was identiﬁ ed by line-probe assay, resistance 
was conﬁ rmed by phenotypic susceptibility testing. 
Fewer MTB/RIF tests were recorded as failures or 
invalid (one of 867, 0·001%) than cultures were recorded 
as contaminated (19 of 867, 2·2%; p<0·0001). MTB/RIF 
provided faster results, within a median of 1 day (IQR 0–4) 
compared with 12 days (IQR 9–17) for culture.
Discussion
Two MTB/RIF tests on induced sputum specimens 
detected three-quarters of culture-conﬁ rmed tuberculosis 
Sensitivity Speciﬁ city Positive 
predictive 
value
Negative 
predictive 
value
Sensitivity (95% CI) for 
smear-positive deﬁ nite 
tuberculosis 
Sensitivity (95% CI) for 
smear-negative deﬁ nite 
tuberculosis
All children with complete results from at least one induced sputum specimen (n=452)
MTB/RIF
All 52/70, 74·3% (63·8–84·8) 376/382, 98·4% (97·2–99·7) 89·7% 95·4% 27/27, 100% (87·2–100) 25/43, 58·1% (42·8–73·5)
HIV-infected 17/17, 100% (80·5–100) 91/91, 100% (96·0–100) 100% 100% 10/10, 100% (69·2–100) 7/7, 100% (59·0–100)
HIV-uninfected 35/53, 66·0% (52·9–79·2) 285/291, 97·9% (96·3–99·6) 85·4% 94·1% 17/17, 100% (80·5–100) 18/36, 50% (32·8–67·2)
Smear microscopy 27/70, 38·6% (26·9–50·3) 382/382, 100% (99·0–100) 100% 89·9% ·· ··
Children with complete results from two induced sputum specimens (n=385)*
MTB/RIF (ﬁ rst induced sputum specimen) 34/58, 58·7% (45·6 –71·1) 325/327, 99·4% (98·5–100) 94·4% 93·1% 22/22, 100% (84·6–100) 12/36, 33·3% (17·2–49·5)
MTB/RIF (both induced sputum specimens)
All 44/58, 75·9% (64·5–87·2) 323/327, 98·8% (97·6–99·9) 91·7% 95·8% 22/22, 100% (84·6–100) 22/36, 61·1% (44·4–77·8)
HIV-infected 14/14, 100% (76·8–100) 80/80, 100% (95·5–100) 100% 100% 9/9, 100% (66·4–100) 5/5, 100% (47·8–100)
HIV-uninfected 30/44, 68·2% (53·9–82·5) 241/245, 98·4% (96·8–99.9) 88·2% 94·5% 13/13, 100% (75·3–100) 17/31, 54·8% (36·3–73·4)
Smear microscopy (two smears)
All 22/58, 37·9% (25·1–50·8) 327/327, 100% (98·9–100) 100% 90·1% ·· ··
Data are number correct/number tested, % (95% CI). *Sensitivity and speciﬁ city calculated with results from both induced sputum cultures.
Table 2: Accuracy of MTB/RIF and smear for case detection with liquid culture as the reference standard 
LPA/DST resistant LPA/DST sensitive LPA/DST inconclusive 
MTB/RIF resistant 2 0 0
MTB/RIF sensitive 0 70 1
MTB/RIF indeterminate 1 4 0
LPA/DST=culture-based drug susceptibility testing (line probe assay).
Table 3: Concordance between MTB/RIF and culture-based drug susceptibility testing for identiﬁ cation 
of resistance to rifampicin (per-sample analysis)
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in young children admitted to hospital with suspected 
pulmonary tuberculosis, with very high speciﬁ city. MTB/
RIF detected all smear-positive cases, but had a lower 
sensitivity in smear-negative cases, with two tests detecting 
about three-ﬁ fths of cases. The yield of MTB/RIF was 
twice that of smear microscopy. This test is widely 
anticipated to replace smear microscopy in resource-poor 
settings where HIV co-infection or drug-resistant 
tuberculosis are common,9 and our results suggest that its 
use is a major improvement over use of smear microscopy. 
Although time to detection was not a primary outcome for 
this study, MTB/RIF results were available within 1 day, 
which was substantially faster than for culture results.
The sensitivity for smear-negative disease was lower 
than that previously reported in adults with suspected 
tuberculosis of 85% for two MTB/RIF tests.8 The 
incremental increase in sensitivity of a second MTB/RIF 
test for smear-negative tuberculosis was substantial. 
WHO recommends one MTB/RIF test for adults with 
suspected tuberculosis,9 but our ﬁ ndings suggest that a 
second test should be recommended in children who 
have a negative ﬁ rst test. The beneﬁ t of improved 
sensitivity of a second test would need to be balanced 
against the increased costs associated with repeat testing.
Although MTB/RIF was more sensitive than smear 
microscopy, almost a quarter of children with culture-
conﬁ rmed tuberculosis were negative on MTB/RIF testing; 
this proportion was even higher in smear-negative, culture-
positive children. Although a positive MTB/RIF test is 
helpful, a negative test should therefore be interpreted in 
the context of the child’s clinical and radiological ﬁ ndings. 
Culture remains an important diagnostic method. 
Most children were treated for tuberculosis on the basis 
of clinical rather than microbiological ﬁ ndings. In view of 
the fact that an ideal test for tuberculosis in children is 
likely to have better sensitivity than culture, culture might 
be an imperfect reference standard. The absence of a highly 
sensitive reference standard makes assessment of this and 
other, potentially more sensitive, future technologies 
challenging. The development of better diagnostic methods 
for childhood tuberculosis remains a major priority.13 
In this study, MTB/RIF detected all cases of deﬁ nite 
tuberculosis in children with HIV. However, because the 
number of children with HIV and culture-proven disease 
was small, further study is needed to conﬁ rm whether 
sensitivity is increased in these patients. 
The speciﬁ city of MTB/RIF was high with only six 
children having a positive MTB/RIF test and at least one 
negative induced sputum culture. Interpretation of the 
results for these six children is diﬃ  cult, because of the 
poor sensitivity of culture for the diagnosis of childhood 
tuberculosis.1 However, these children probably had 
pulmonary tuberculosis because they all had a good 
clinical response to treatment at follow-up visits. The 
true speciﬁ city of MTB/RIF might be even higher, 
because none of the 166 children in whom tuberculosis 
was excluded had a positive MTB/RIF test. 
Sputum induction was not regarded as feasible for 
diagnosis in young children until about 6 years ago. 
Several studies have now shown the eﬃ  cacy and safety of 
sputum induction in infants and young children, 
particularly in those who have been admitted to hospital.5,14,15 
However, data on the use of sputum induction in primary 
care facilities, where the major burden of childhood 
tuberculosis occurs, are scarce (panel). If MTB/RIF testing 
is to be implemented at or close to the point of care, then 
the capacity for sputum induction in children at health 
facilities will need to be scaled up. More widespread use of 
sputum induction in children poses operational 
challenges, including training of staﬀ , operator time, and 
the need for precautions to prevent transmission. For 
ambulatory children, two induced sputum procedures 
necessitate a second visit or an extended stay at a health 
facility. In our study, MTB/RIF testing was done at a large 
diagnostic laboratory in an academic centre; however, the 
test is robust and can be easily and competently done at 
microscopy centres.22
MTB/RIF is designed to detect not only the presence of 
tuberculosis, but also RIF resistance. This study was 
primarily aimed at assessment of the use of MTB/RIF for 
tuberculosis detection. Because few rifampicin-resistant 
cases were detected in this study, we are unable to draw 
conclusions about the ability of MTB/RIF to detect 
resistance. Further limitations of this study include the few 
children with HIV infection and culture-conﬁ rmed disease, 
and the need to split sputum sediment between culture 
and MTB/RIF testing. MTB/RIF is designed for use directly 
on sputum specimens, rather than on sputum pellet. 
However a study in adults showed equivalent performance 
for both specimen types.8 For this study we chose to split 
Panel: Research in context
Systematic review
We searched PubMed for studies about the Xpert MTB/RIF test published in English up to 
June 14, 2011, with the search terms “Xpert” or “MTB/RIF” and “tuberculosis”. We did not 
identify any systematic reviews. We identiﬁ ed eight studies that assessed the use of MTB/RIF 
for detection of tuberculosis in respiratory specimens, all of which were in adult patients.8,14,16–21
Interpretation
Most studies, apart from a large multicentre study8 and a multicentre demonstration study,14 
were small, with many including testing of archived samples. The sensitivity of MTB/RIF for 
detection of smear-positive tuberculosis varied between 95% and 100%, with most studies 
reporting sensitivity of 99–100%. Sensitivity for smear-negative tuberculosis varied 
substantially, between 47% and 77%. In studies with adequate numbers of rifampicin-
resistant samples, sensitivity for detection of rifampicin resistance varied between 94% and 
100%, and speciﬁ city varied between 98% and 100%. Our study adds to these ﬁ ndings by 
documenting the accuracy of MTB/RIF on induced sputum specimens for the detection of 
culture-conﬁ rmed tuberculosis in children, a previously unreported population. We showed 
that the sensitivity of MTB/RIF for smear-negative tuberculosis is lower in children that it is in 
adults, but is twice as sensitive compared with smear microscopy in children. We also showed 
that the incremental beneﬁ t in testing a second induced sputum specimen is substantial, 
suggesting that, in children, a second specimen should be tested to optimise sensitivity.
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the sputum pellet for tests to obtain a direct comparison of 
culture and MTB/RIF on the same specimen. In view of 
the paucibacillary nature of childhood tuberculosis, had we 
processed one specimen by MTB/RIF and the other by 
culture, we would have had many discrepant results, which 
would have been diﬃ  cult to interpret. Because induced 
sputum specimens are typically very low volume, and 
M tuberculosis bacilli are probably lost during the specimen 
decontamination process, direct testing of induced sputum 
specimens with MTB/RIF (when the whole specimen 
volume would be used) might have improved sensitivity 
compared with testing of the pellet. 
This study enrolled children who were admitted to a 
secondary or tertiary care facility, who could have had 
more severe disease than those seen in primary care 
settings. However, these hospitals are major referral 
centres for children across the Greater Cape Town region. 
This urban area has one of the highest rates of tuberculosis 
in South Africa, but has good access to health services.23 
The performance of MTB/RIF might diﬀ er in children 
with less severe illness or in other settings where the 
spectrum of illness is not the same because of diﬀ ering 
access to health care; further studies are needed. Further 
work is also needed to assess MTB/RIF with other, easily 
obtained specimen types, such as urine and stool.
MTB/RIF is a reliable test for rapid diagnosis of 
tuberculosis in children when used on induced sputum 
specimens. Testing two specimens substantially increases 
diagnostic yield for smear-negative tuberculosis. To 
maximise the eﬀ ect of this technology and beneﬁ t child 
health, increased capacity for sputum induction in 
children at health-care facilities is needed. 
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